StreetInsider.com News Articles

Canaccord Starts First Tracks Biotherapeutics (TRAX) at Buy

Wed, 30 Sep 2026 06:55:06 -0400

(Updated - September 30, 2026 6:55 AM EDT)

Canaccord analyst Edward Nash initiates coverage on First Tracks Biotherapeutics (NASDAQ: TRAX) with a Buy rating and a price target of $50.00.

The analyst comments "We are initiating coverage of First Tracks Biotherapeutics with a BUY rating and 12- month price target of $50. The company, a spin-off from AnaptysBio, has three clinical- stage assets: ANB033, rosnilimab, and ANB101. ANB033 accounts for approximately 95% of our assigned value and is currently being evaluated in two Phase Ib trials, with top-line data expected in celiac disease (CeD) in 4Q26 and 1Q27 and in eosinophilic esophagitis

Canaccord Starts First Tracks Biotherapeutics (TRAX) at Buy

Wed, 30 Sep 2026 06:55:06 -0400

(Updated - September 30, 2026 6:55 AM EDT)

Canaccord analyst Edward Nash initiates coverage on First Tracks Biotherapeutics (NASDAQ: TRAX) with a Buy rating and a price target of $50.00.

Evercore ISI Starts First Tracks Biotherapeutics (TRAX) at Outperform

Fri, 18 Sep 2026 06:06:30 -0400

Evercore ISI initiates coverage on First Tracks Biotherapeutics (NASDAQ: TRAX) with a Outperform rating and a price target of $65.00.

For an analyst ratings summary and ratings history on First Tracks Biotherapeutics click here. For more ratings news on First Tracks Biotherapeutics click here.

Shares of First Tracks Biotherapeutics closed at $39.20 yesterday.

Form 4 First Tracks Biotherapeu For: Sep 15 Filed by: Orwin John A

Thu, 17 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260917/27075837.html

Form 4 First Tracks Biotherapeu For: Sep 15 Filed by: Orwin John A

Thu, 17 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260917/27075837.html

This biotech stock is a new Top Pick at Guggenheim

Thu, 17 Sep 2026 14:00:00 -0400

Guggenheim named a biotech name as a new top pick in a note on Thursday, initiating coverage with a Buy rating and $100 price target.

The stock in question is First Tracks Biotherapeutics (NASDAQ: TRAX). The firm's thesis centers on high conviction in the anti-CD122 target and lead asset ANB033, which it sees having potential across multiple autoimmune diseases.

Guggenheim said it flagged CD122/IL-15 as "one of immunology's most consequential undeveloped targets" back in January 2025 and has since seen substantial clinical progress.

"TRAX is a new Top Pick," the firm wrote, noting First Tracks is the only publicly traded small- or

This biotech stock is a new Top Pick at Guggenheim

Thu, 17 Sep 2026 14:00:00 -0400

Guggenheim named a biotech name as a new top pick in a note on Thursday, initiating coverage with a Buy rating and $100 price target.

Guggenheim said it flagged CD122/IL-15 as "one of immunology's most consequential undeveloped targets" back in January 2025 and has since seen substantial clinical progress.

"TRAX is a new Top Pick," the firm wrote, noting First Tracks is the only publicly traded small- or

Guggenheim Starts First Tracks Biotherapeutics (TRAX) at Buy,

Wed, 16 Sep 2026 03:13:54 -0400

Guggenheim analyst Yatin Suneja initiates coverage on First Tracks Biotherapeutics (NASDAQ: TRAX) with a Buy rating and a price target of $100.00.

The analyst comments: “Our TRAX thesis centers on high conviction in anti-CD122 target and lead asset ANB033, with potential across multiple autoimmune diseases. We flagged CD122/IL-15 as one of immunology's most consequential undeveloped targets back in Jan 2025 (see HERE), and we have witnessed substantial clinical progress in this target. To-date, CD122/IL-15 remains one of the very few underdeveloped targets in autoimmunity, and we anticipate a burst of indication expansions with well-validated genetics and T-cell pathology. Early clinical success

Guggenheim Starts First Tracks Biotherapeutics (TRAX) at Buy,

Wed, 16 Sep 2026 03:13:54 -0400

Guggenheim analyst Yatin Suneja initiates coverage on First Tracks Biotherapeutics (NASDAQ: TRAX) with a Buy rating and a price target of $100.00.

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

Wed, 26 Aug 2026 16:15:00 -0400

SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:

21^st Annual Wells Fargo Healthcare Conference, Boston

Format – Fireside chat and one-on-one investor meetings
Date and Time – Wednesday, Sept. 9, 2026 at 9:30am ET / 6:30am PT

Citi's 2026 Biopharma Back to School Conference, New York City

Format – One-on-one investor meetings
Date

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

Wed, 26 Aug 2026 16:15:00 -0400

21^st Annual Wells Fargo Healthcare Conference, Boston

Format – Fireside chat and one-on-one investor meetings
Date and Time – Wednesday, Sept. 9, 2026 at 9:30am ET / 6:30am PT

Citi's 2026 Biopharma Back to School Conference, New York City

Format – One-on-one investor meetings
Date

Form 4 First Tracks Biotherapeu For: Aug 15 Filed by: STONE BENJAMIN

Tue, 18 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260818/26944186.html

Form 4 First Tracks Biotherapeu For: Aug 15 Filed by: STONE BENJAMIN

Tue, 18 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260818/26944186.html

Form 4 First Tracks Biotherapeu For: Aug 15 Filed by: STONE BENJAMIN

Tue, 18 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260818/26944186.html

Form 4 First Tracks Biotherapeu For: Aug 15 Filed by: Faga Daniel